UBS Global Healthcare Conference - DAVITA INC

Explicit Guidance:

• FY2027 Revenue/Volume: Expects positive volume growth in FY2027, targeting a return to pre-pandemic levels of 2%+ annual growth by 2029; FY2027 volume is projected to outperform FY2026.
• FY2027 Financial Headwinds: Anticipates a ~$70 million negative impact on operating income in FY2027 resulting from the expiration of enhanced premium tax credits and the subsequent shift of exchange patients to Medicare/Medicare Advantage (downward mix shift on new admissions).
• FY2027 Revenue Rate: Estimates an effective full-year Medicare ESRD payment increase of 1.5% to 2.0% for 2027, despite a headline Q1 2027 rate of 3.5%, driven by lagging DAPA add-on payment dynamics.
• FY2027 Cost Mitigation: Projects pharmaceutical cost savings in 2027 will exceed normal levels due to contracting, generic conversion, and clinical protocol changes, aiming to offset the $70M revenue headwind and underfunding of FFS rates.
• IT Spend: Foresees IT expense growth decelerating in FY2027 to "well above normal" rates but below the >20% annual growth seen in the previous four years, though absolute spend will not decline.
• Cash Flow & Capital Allocation: Guides free cash flow generation of $1.0B to $1.25B; maintains a target leverage ratio of 3.0x–3.5x; commits to continued share buybacks barring unique M&A opportunities.

Business-Segment Outlook:

• International: Projected to deliver ~1% operating income growth, consistent with long-term expectations.
• Inpatient Kidney Care (IKC): Expected to contribute ~2% to operating income growth in the current year (vs. historical 1%); business is deemed "hitting its stride" with sustainable profitability.
• U.S. Dialysis: Volume growth is solidifying in the current year; revenue per treatment (RPT) is stronger than anticipated. Cost headwinds from IT and G&A remain a challenge but are expected to moderate in 2027.
• IKC Partnerships: A new 10,000-patient relationship with Humana (CKD segment) is expected to create a near-term economic headwind in H2 FY2026 and H1 FY2027 before generating revenue.

Market and Competitive Outlook:

• Volume Drivers: 2027 volume growth is supported by a 50 basis point tailwind from calendar day alignment (vs. a 25 bps headwind in current year) and 25 bps of non-recurring benefit removal from FY2026 clinic closures.
• Treatment Modality Expansion: Broad rollout of expanded hemodialysis (high-flux/dialyzers) scheduled for November; financial impact (mortality benefits translating to volume) expected to materialize in H2 FY2028, with full realization by 2029.
• Competitive Positioning: Management asserts scale advantages in pharmaceutical negotiations allow for cost reductions smaller competitors cannot achieve, positioning the company as a cost solution.

Macro / Industry Outlook:

• Regulatory (2027 Rule): CMS 2027 rule dynamics are expected to create an underfunding gap between Medicare FFS rate increases and nominal treatment cost trends.
• Policy (Premium Tax Credits): View on the expiration of enhanced premium tax credits indicates a structural shift in payer mix; believes eliminating charitable premium assistance would hurt patients and increase government costs without driving competition.
• Economic Environment: Acknowledges potential macro pressure on commercial mix; no specific forecast on broader economic indicators other than their impact on patient coverage retention.

Strategic Initiatives:

• Technology Investment: Continued heavy investment in AI and core systems maturation; AI initiatives are expected to yield returns in FY2027 through improved clinical protocols and cost savings.
• Clinical Innovation: Accelerated deployment of expanded HD; pursuing additional clinical initiatives in fluid management, vaccination, and pharmaceutical dosing to support 2% volume growth targets.
• M&A/Investment: Open to capital deployment for growth/innovation (e.g., Home Health, Latin America, Alara) but defaults to share buybacks with free cash flow absent specific targets.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Final dynamics of DAPA add-on payments and ASP calculations remain opaque, creating variance in the 1.5%–2.0% effective Medicare rate estimate.
• Patient Mix Shift: The pace of commercial-to-Medicare conversion among new dialysis admissions is a key variable; slower retention of commercial coverage on exchanges could exacerbate the $70M headwind.
• Operational/Clinical Variability: Mistreatment rates, flu season, mortality, and acute care admission trends in Q4 and FY2027 remain volatile and could impact volume.
• Cost Realization Risk: Pharmaceutical cost savings depend on physician prescribing behavior and successful formulary adoption of AI-driven protocols.
• IKC Engagement: Challenges in engaging CKD patients in the Humana partnership could delay revenue generation.

Management Tone on the Future:

• Confidence Level: Cautiously optimistic regarding volume recovery and the sustainability of the IKC business; confident in the company's ability to mitigate revenue headwinds through pharma and operational efficiencies.
• Hedges: Management explicitly states they are "not banking on" clinical trial-level mortality improvements driving immediate volume and notes that "real life and clinical trials are very different scenarios."
• Guidance Changes: Shifts focus from specific 2027 earnings targets to emphasizing the "two components" of mitigation (volume growth and pharma savings) rather than simply subtracting the exchange headwind from prior trends.

Miscellaneous:

• Binder Payments: The separate $1,285 binder payment is locked for 2027 but expected to be integrated into the main bundle and disappear as a distinct line item in 2028.
• FENCAFP (Defib/Cath) Revenue: Expectation of a sharp decline in this specific reimbursement component after Q4 2027 due to ASP and utilization declines typical of post-DAPA lifecycle.